Clinical trial · Interventional
PET Response During Chemoradiation of Lung Cancer
Dynamic FDG-PET/CT Response During Chemoradiation for NSCLC
NCT02315053CI-TRIAL-00030099completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective observational study to determine the prognostic value of the timing of 50% reduction in metabolic activity (T50) during CCRT for NSCLC for treatment outcome (PFS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low dose FDG PET/CT 5 x. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Low dose FDG PET/CT 5x
- description
- Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
- interventionNames
- Other: Low dose FDG PET/CT 5 x.
Primary outcomes (1)
- measure
- maximum FDG uptake (SUVmax)
- timeFrame
- 1 Year
- description
- • A main study parameter is the maximum FDG uptake (SUVmax (maximum Standardized Uptake Value)) at the location of the primary tumour, as determined at multiple days during treatment (with a maximum of five time points per patient), expressed as T50 for response evaluation.
Secondary outcomes (3)
- measure
- SUVmax during the first two weeks of treatment, indicating inflammatory response.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cytologically or histologically proven NSCLC * T2-4 N0-3 M0 disease (stage II or III, inoperable) * Scheduled for standard concurrent chemoradiation * Primary tumour minimal diameter 3 cm * Primary tumour SUVmax \> 5 on routine diagnostic pre-treatment FDG (Fludeoxyglucose) PET/CT * WHO performance 0-1 * Written informed consent according to GCP (Good Clinical Practice) and national regulations Exclusion Criteria: * Age \< 18 years, incapacitated subjects * Pregnant or lactating women * Diabetes mellitus requiring medication * Participation in dose escalation studies * Other neoplasms in the last 3 years, with metastases
References
Publications (0)
Data not yet available
No reference posted for this study.